Tag: lexaria bioscience corp

Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy

Lexaria Bioscience Corp. is pleased to review its successful 2021 antiviral drug program to date and summarize expected next steps.

Lexaria’s DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3

Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce that its tolerability and pharmacokinetic study...

Lexaria Bioscience CEO: Faster, Cost-efficient Drug Delivery Platform for COVID-19 and Beyond

Lexaria Bioscience CEO Chris Bunka discusses the technology’s potential to treat viral infections via oral delivery and help save billions...

Lexaria Bioscience Confirms Closing of US$2,039,228 Private Placement

Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) confirms that its private placement financing.

Lexaria Bioscience Announces Over US$2,000,000 Private Placement

Lexaria Bioscience has entered into definitive agreements with certain qualified investors for the sale of share and warrants to purchase...

Lexaria Receives Notice of Allowance for New Patent and Awards Stock Options

Lexaria Bioscience (CSE:LXX) a global innovator in drug delivery platforms, has received a Notice of Allowance from the United States...

Lexaria Bioscience Files New Patent Utilizing DehydraTECH Technology for Treatment of Infectious Diseases Including COVID-19

Lexaria (CSE:LXX) has filed a new patent application in the US describing the use of its DehydraTECH(TM) technology for the...